vs
ALLIANCE ENTERTAINMENT HOLDING CORP（AENT）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
ALLIANCE ENTERTAINMENT HOLDING CORP的季度营收约是Apellis Pharmaceuticals, Inc.的1.8倍（$368.7M vs $199.9M），ALLIANCE ENTERTAINMENT HOLDING CORP净利率更高（2.5% vs -29.5%，领先32.0%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -6.3%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-16.9M），过去两年ALLIANCE ENTERTAINMENT HOLDING CORP的营收复合增速更高（32.1% vs 7.7%）
该企业是一家总部位于加拿大多伦多的传媒公司，核心业务为加拿大市场提供专业特色媒体服务，除多伦多总部外，还在哈利法克斯、洛杉矶、伦敦、都柏林、马德里、巴塞罗那、香农以及悉尼多地设有办事机构。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
AENT vs APLS — 直观对比
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $368.7M | $199.9M |
| 净利润 | $9.4M | $-59.0M |
| 毛利率 | — | — |
| 营业利润率 | 4.7% | -25.6% |
| 净利率 | 2.5% | -29.5% |
| 营收同比 | -6.3% | -5.9% |
| 净利润同比 | 32.8% | -62.2% |
| 每股收益（稀释后） | $0.18 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $368.7M | $199.9M | ||
| Q3 25 | $254.0M | $458.6M | ||
| Q2 25 | $227.8M | $178.5M | ||
| Q1 25 | $213.0M | $166.8M | ||
| Q4 24 | $393.7M | $212.5M | ||
| Q3 24 | $229.0M | $196.8M | ||
| Q2 24 | $236.9M | $199.7M | ||
| Q1 24 | $211.2M | $172.3M |
| Q4 25 | $9.4M | $-59.0M | ||
| Q3 25 | $4.9M | $215.7M | ||
| Q2 25 | $5.8M | $-42.2M | ||
| Q1 25 | $1.9M | $-92.2M | ||
| Q4 24 | $7.1M | $-36.4M | ||
| Q3 24 | $397.0K | $-57.4M | ||
| Q2 24 | $2.5M | $-37.7M | ||
| Q1 24 | $-3.4M | $-66.4M |
| Q4 25 | 4.7% | -25.6% | ||
| Q3 25 | 4.2% | 48.7% | ||
| Q2 25 | 4.3% | -18.6% | ||
| Q1 25 | 1.7% | -50.0% | ||
| Q4 24 | 3.8% | -12.3% | ||
| Q3 24 | 0.9% | -24.0% | ||
| Q2 24 | 0.2% | -14.7% | ||
| Q1 24 | -0.3% | -36.0% |
| Q4 25 | 2.5% | -29.5% | ||
| Q3 25 | 1.9% | 47.0% | ||
| Q2 25 | 2.5% | -23.6% | ||
| Q1 25 | 0.9% | -55.3% | ||
| Q4 24 | 1.8% | -17.1% | ||
| Q3 24 | 0.2% | -29.2% | ||
| Q2 24 | 1.1% | -18.9% | ||
| Q1 24 | -1.6% | -38.5% |
| Q4 25 | $0.18 | $-0.40 | ||
| Q3 25 | $0.10 | $1.67 | ||
| Q2 25 | $0.11 | $-0.33 | ||
| Q1 25 | $0.04 | $-0.74 | ||
| Q4 24 | $0.14 | $-0.30 | ||
| Q3 24 | $0.01 | $-0.46 | ||
| Q2 24 | $0.05 | $-0.30 | ||
| Q1 24 | $-0.07 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $466.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $117.6M | $370.1M |
| 总资产 | $434.1M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $466.2M | ||
| Q3 25 | — | $479.2M | ||
| Q2 25 | — | $370.0M | ||
| Q1 25 | — | $358.4M | ||
| Q4 24 | — | $411.3M | ||
| Q3 24 | $4.3M | $396.9M | ||
| Q2 24 | $1.1M | $360.1M | ||
| Q1 24 | $1.6M | $325.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $93.1M |
| Q4 25 | $117.6M | $370.1M | ||
| Q3 25 | $108.1M | $401.2M | ||
| Q2 25 | $103.2M | $156.3M | ||
| Q1 25 | $97.4M | $164.2M | ||
| Q4 24 | $95.6M | $228.5M | ||
| Q3 24 | $88.0M | $237.1M | ||
| Q2 24 | $87.6M | $264.3M | ||
| Q1 24 | $85.1M | $266.7M |
| Q4 25 | $434.1M | $1.1B | ||
| Q3 25 | $383.0M | $1.1B | ||
| Q2 25 | $361.2M | $821.4M | ||
| Q1 25 | $349.4M | $807.3M | ||
| Q4 24 | $401.7M | $885.1M | ||
| Q3 24 | $395.7M | $901.9M | ||
| Q2 24 | $340.8M | $904.5M | ||
| Q1 24 | $324.0M | $831.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.5M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | $-16.9M | $-14.3M |
| 自由现金流率自由现金流/营收 | -4.6% | -7.1% |
| 资本支出强度资本支出/营收 | 0.1% | 0.1% |
| 现金转化率经营现金流/净利润 | -1.76× | — |
| 过去12个月自由现金流最近4个季度 | $-1.4M | $45.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-16.5M | $-14.2M | ||
| Q3 25 | $2.7M | $108.5M | ||
| Q2 25 | $10.7M | $4.4M | ||
| Q1 25 | $2.5M | $-53.4M | ||
| Q4 24 | $25.3M | $19.4M | ||
| Q3 24 | $-11.6M | $34.1M | ||
| Q2 24 | $9.7M | $-8.3M | ||
| Q1 24 | $20.0M | $-133.0M |
| Q4 25 | $-16.9M | $-14.3M | ||
| Q3 25 | $2.4M | $108.3M | ||
| Q2 25 | $10.7M | $4.4M | ||
| Q1 25 | $2.4M | $-53.4M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | $-11.6M | — | ||
| Q2 24 | — | $-8.4M | ||
| Q1 24 | $20.0M | $-133.3M |
| Q4 25 | -4.6% | -7.1% | ||
| Q3 25 | 0.9% | 23.6% | ||
| Q2 25 | 4.7% | 2.5% | ||
| Q1 25 | 1.1% | -32.0% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | -5.1% | — | ||
| Q2 24 | — | -4.2% | ||
| Q1 24 | 9.4% | -77.3% |
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | 0.0% | 0.2% |
| Q4 25 | -1.76× | — | ||
| Q3 25 | 0.56× | 0.50× | ||
| Q2 25 | 1.86× | — | ||
| Q1 25 | 1.33× | — | ||
| Q4 24 | 3.57× | — | ||
| Q3 24 | -29.31× | — | ||
| Q2 24 | 3.85× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AENT
暂无分部数据
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
